乐纯生物筹备上市，注册资本3.63亿元、斯坦利思等参与投资

Core Insights - Shanghai Lechun Biotechnology Co., Ltd. has disclosed its IPO counseling progress report (ninth phase) with China International Capital Corporation as the counseling institution [2] - Established in 2011, Lechun Biotechnology has a registered capital of 363 million yuan and operates in four main areas: single-use systems, filtration and purification, cell culture, and cleanroom contamination control [2] - The company has completed financing and acquisition plans for several entities, including Ge's Fluid, Kangsheng Biotechnology, Stanley Think, and Feiding, between 2023 and 2024 [2]